Ryan Allway January 19th, 2021 Psychedelics Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. (“Divergence”), a company focused on the research and development of a data-driven, cloud-based... Read more

Ryan Allway January 18th, 2021 Psychedelics Cybin Inc. (NEO: CYBN) (“Cybin” or the “Company“), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord” or the “Lead Underwriter“) on behalf of a syndicate of... Read more

Ryan Allway January 15th, 2021 Psychedelics Numinus Wellness Inc. (“Numinus“) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, announces that it has granted 1,975,000 incentive stock options (the “Options“) to directors, officers and employees... Read more

Ryan Allway January 15th, 2021 Psychedelics EGF Theramed Health Corp. (CSE:TMED)(OTCQB:EVAHF) is pleased to announce that it has completed the first tranche of its previously announced (December 10, 2020) offering (the “Offering“), issuing 2,937,516 units (each a “Unit“) by way of non-brokered private placement at a price of $0.12... Read more

Ryan Allway January 15th, 2021 Psychedelics Optimi Health Corp. (“Optimi”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that it has filed a preliminary prospectus (the “Preliminary Prospectus”) with the securities regulatory authorities in each of the provinces... Read more

Ryan Allway January 15th, 2021 Psychedelics Awakn Life Sciences announced today the selection of contract research organization (‘CRO’), PRA Health Sciences (NASDAQ: PRAH), to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent (‘Harmful Use’) Alcohol Use Disorder (“AUD”).... Read more

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more

Ryan Allway January 14th, 2021 Psychedelics NEW WAVE HOLDINGS CORP. (“New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, is pleased to announce its launch of high quality new functional mushroom wellness collection under Way of Will Inc. WAY OF WILL... Read more

Ryan Allway January 14th, 2021 Psychedelics TORONTO, Jan. 14, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has... Read more